151 related articles for article (PubMed ID: 34237262)
21. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial.
Barreto ML; Pereira SM; Pilger D; Cruz AA; Cunha SS; Sant'Anna C; Ichihara MY; Genser B; Rodrigues LC
Vaccine; 2011 Jul; 29(31):4875-7. PubMed ID: 21616115
[TBL] [Abstract][Full Text] [Related]
22. The distribution and implications of BCG scars in northern Malawi.
Fine PE; Ponnighaus JM; Maine N
Bull World Health Organ; 1989; 67(1):35-42. PubMed ID: 2706726
[TBL] [Abstract][Full Text] [Related]
23. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
Prentice S; Nassanga B; Webb EL; Akello F; Kiwudhu F; Akurut H; Elliott AM; Arts RJW; Netea MG; Dockrell HM; Cose S;
Lancet Infect Dis; 2021 Jul; 21(7):993-1003. PubMed ID: 33609457
[TBL] [Abstract][Full Text] [Related]
24. Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2.
Ramos-Martinez E; Falfán-Valencia R; Pérez-Rubio G; Andrade WA; Rojas-Serrano J; Ambrocio-Ortiz E; Galicia-Álvarez DS; Bárcenas-Montiel I; Velasco-Medina A; Velázquez-Sámano G
Cells; 2021 Nov; 10(11):. PubMed ID: 34831403
[TBL] [Abstract][Full Text] [Related]
25. Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults.
Black GF; Weir RE; Chaguluka SD; Warndorff D; Crampin AC; Mwaungulu L; Sichali L; Floyd S; Bliss L; Jarman E; Donovan L; Andersen P; Britton W; Hewinson G; Huygen K; Paulsen J; Singh M; Prestidge R; Fine PE; Dockrell HM
Clin Diagn Lab Immunol; 2003 Jul; 10(4):602-11. PubMed ID: 12853392
[TBL] [Abstract][Full Text] [Related]
26. Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial.
Usher NT; Chang S; Howard RS; Martinez A; Harrison LH; Santosham M; Aronson NE
JAMA Netw Open; 2019 Sep; 2(9):e1912014. PubMed ID: 31553471
[TBL] [Abstract][Full Text] [Related]
27. Design of the leprosy component of the Brazilian BCG revaccination trial for assessing BCG effectiveness against leprosy in school children.
Cunha SS; Dourado I; Barreto ML; Alexander N; Pereira SM; Ichihara Y; Pereira ES; Pedrosa V; Maroja F; Ribas C; Rodrigues LC
Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):8-15. PubMed ID: 15217320
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
[TBL] [Abstract][Full Text] [Related]
29. Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.
Ghazi Saidi K; Stanford JL; Stanford CA; Dowlati Y; Farshchi Y; Rook GA; Rees RJ
Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):45-53. PubMed ID: 2659701
[TBL] [Abstract][Full Text] [Related]
30. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.
Leung CC; Tam CM; Chan SL; Chan-Yeung M; Chan CK; Chang KC
Int J Tuberc Lung Dis; 2001 Aug; 5(8):717-23. PubMed ID: 11495262
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
[TBL] [Abstract][Full Text] [Related]
36. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A; Nassanga B; Natukunda A; Serubanja J; Tumusiime J; Akurut H; Oduru G; Nassuuna J; Kabagenyi J; Morrison H; Scott H; Doherty RP; Marshall JL; Puig IC; Cose S; Kaleebu P; Webb EL; Satti I; McShane H; Elliott AM;
Lancet Infect Dis; 2024 Mar; 24(3):285-296. PubMed ID: 38012890
[TBL] [Abstract][Full Text] [Related]
39. BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size.
Floyd S; Ponnighaus JM; Bliss L; Warndorff DK; Kasunga A; Mogha P; Fine PE
Int J Tuberc Lung Dis; 2000 Dec; 4(12):1133-42. PubMed ID: 11144455
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
